Eli Lilly and Company

Company Description
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company's products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company's new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In January 2014, acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody.
Contact Information
Lilly Corporate Center
INDIANAPOLIS, IN 46285
UNITED STATES
Phone: (317) 276-2000
Fax: (317) 276-3492
Investor Relations
Corporate History/Profile
Employment Opportunities
Executives
Financial Information
News Releases
Products/Services